Effect Of Her-2 Gene On Anthracycline Adjuvant Chemotherapy Efficacy In Breast Cancer

Objective We explore the relationship between Expression of HER-2 gene and anthracycline adjuvant chemotherapy efficacy in breast cancer patients,to provide a theoretical basis for individualized treatment .Methods The survival state of 204 cases of invasive breast cancer patients inⅡstage was systematicly reviewed after adjuvant chemotherapy with anthracycline drugs, the median follow-up 37.00 (13.2 to 60.1) months. The expression of HER-2 and ER in tumor samples was detected by MaxVisionTM quickly immunohistochemistry. 204 patients were further divided into groups combinated with HER-2-based estrogen receptor and axillary lymph nodes, and contrasted the difference of disease-free survival in patients with different pathological features in each group with the application of anthracycline chemotherapy.Results After the average follow-up 36 months, the total recurrence rate was 35.29% (72/204), mortality rate was 22.55% (46/204). (1)Overall, DFS in HER-2 positive patients was higher than that in HER-2 negative patients, P <0.05.(2)DFS in HER-2 positive and ER-positive patients was higher than that in HER-2 negative and ER positive patients, P >0.05. (3)DFS in HER-2 positive and ER negative patients was higher than that in HER-2 negative and ER negative patients, P> 0.05. (4)In the same HER-2 expression patients, DFS was not significantly different regardless of ER-negative or ER-positive, P> 0.05. (5)In ER-negative and lymph node-negative patients, DFS in Her-2 negative group was lower than that in Her-2 positive group, P <0.05(6)In ER-negative and lymph node-positive patients, DFS in Her-2 negative group was higher than that in Her-2 positive group, P> 0.05. ( 7 ) In ER-positive and lymph node-negative patients, DFS in Her-2 negative group was lower than that in Her-2 positive group, P> 0.05. (8)In ER-positive and lymph node-positive patients, DFS in Her-2 negative group was lower than that in Her-2 positive group, P< 0.05.(9)In the Her-2 negative group, disease free survival in ER-negative and node-negative patients was lower than that in ER-negative and node-positive patients, P>0.05; disease free survival in ER-positive and lymph node-negative patients was higher than that in ER-positive and lymph node-positive patients, P> 0.05.(10)In the Her-2 positive groups, disease free survival in ER-negative and node-negative patients was higher than that in ER-negative and node-positive patients, P>0.05;disease free survival in ER-positive and lymph node-negative patients was higher than that in ER-positive and positive lymph nodes patients, P> 0.05. (11)In the Her-2 negative group, disease free survival in ER-negative and node-negative patients was lower than that in ER-negative and node-positive patients, P>0.05; disease free survival in ER-positive and lymph node-negative patients was higher than that in ER-positive and lymph node-positive patients, P> 0.05.(12)In the Her-2 positive groups, disease free survival in ER-negative and node-negative patients was higher than that in ER-negative and node-positive patients, P>0.05;disease free survival in ER-positive and lymph node-negative patients was higher than that in ER-positive and positive lymph nodes patients, P> 0.05.Conclusion (1) body in terms of clinical stageⅡpatients with invasive breast cancer, HER-2 positive patients, HER-2 negative patients than the more from anthracycline adjuvant chemotherapy benefit. (2) HER-2 expression may predict the clinical status of breast cancer patients with stageⅡanthracycline chemotherapy efficacy indicators, especially for ER, lymph nodes were negative and ER, lymph nodes were positive for two types of groups of patients. (3) combined estrogen receptor status and lymph node metastasis may be further screened positive for HER-2 on non-anthracycline-sensitive and ER-2 negative on the relative anthracycline-sensitive breast cancer patients with clinical stageⅡgroup...